Daewon to expand indications of felubiprofen

The Korea Food and Drug Administration gave its nod to the local clinical trials of Daewon’s felubiprofen (brandname: Peluvi), a nonsteroidal anti-inflammatory drug, aiming at expanding indications, such as lumbago.

Daewon said the local clinical trial is to be completed in the latter half of next year with a 3 billion treatment.

Felubiprofen is Korea’s 12th homegrown anti-inflammatory ag...